Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial

The efficacy and possible role of epidermal growth factor receptor tyrosine kinase inhibitors in treating early-stage non-small-cell lung cancer have yet to be established. Therefore, we aimed to explore the efficacy and safety of icotinib in completely resected EGFR-mutant stage II–IIIA lung adenoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu-Tao, Hao, Xue-Zhi, Liu, De-Ruo, Cheng, Gang, Zhang, Shu-Cai, Xiao, Wen-Hua, Hu, Yi, Liu, Jun-Feng, He, Ming, Ding, Cui-Min, Zhang, Li, Wang, Jun, Li, Hui, Dong, Gui-Lan, Zhi, Xiu-Yi, Li, Jian, Shi, Yuan-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306474/
https://www.ncbi.nlm.nih.gov/pubmed/32606956
http://dx.doi.org/10.2147/CMAR.S240275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306474/
https://www.ncbi.nlm.nih.gov/pubmed/32606956
http://dx.doi.org/10.2147/CMAR.S240275

Ejemplares similares